{"id":41873,"date":"2025-09-19T15:48:12","date_gmt":"2025-09-19T07:48:12","guid":{"rendered":"https:\/\/flcube.com\/?p=41873"},"modified":"2025-09-19T15:48:13","modified_gmt":"2025-09-19T07:48:13","slug":"guangdong-taienkang-secures-nmpa-approval-for-safinamide-generic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41873","title":{"rendered":"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic"},"content":{"rendered":"\n<p><strong>Guangdong Taienkang Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/301263:SHE\">SHE: 301263<\/a>) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for <strong>safinamide tablets<\/strong>, approving the drug as a Category\u202f4 chemical product. The decision paves the way for Taienkang\u2019s version of the Parkinson\u2019s disease (PD) adjunctive therapy to reach Chinese patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-safinamide\">About Safinamide<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Safinamide is a selective monoamine oxidase\u2011B (MAO\u2011B) inhibitor that enhances dopaminergic transmission and reduces motor fluctuations in PD.<\/li>\n\n\n\n<li><strong>Origin<\/strong>: The drug was first developed by Italy\u2019s Zambon Group under the brand name <strong>Xadago<\/strong> and is indicated for adults with idiopathic PD who require stable levodopa (L\u2011dopa) regimens, with or without other PD medications.<\/li>\n\n\n\n<li><strong>Market Gap<\/strong>: In China, only the originator product is currently approved. Taienkang\u2019s generic has the potential to become the first locally produced safinamide, offering a more affordable option for patients and payers.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Advantage<\/strong>: The approval positions Taienkang as a key player in the growing Chinese neuro\u2011pharma market, which is expected to exceed <strong>US$5\u202fbillion<\/strong> by 2030.<\/li>\n\n\n\n<li><strong>Pricing &amp; Access<\/strong>: A generic entry could lower treatment costs for the ~1.5\u202fmillion PD patients in China, potentially boosting market penetration and volume.<\/li>\n\n\n\n<li><strong>Regulatory Momentum<\/strong>: The Category\u202f4 registration streamlines post\u2011marketing surveillance and can accelerate the launch of subsequent generic products.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<p>Taienkang plans to initiate a phase\u2011of\u2011market launch and distribution strategy in Q4\u202f2025, coordinating with hospitals, neurology clinics, and insurance providers to facilitate reimbursement and patient access. The company also intends to explore collaborative research with academic institutions to further validate safinamide\u2019s efficacy in the Chinese population.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u6cf0\u6069\u5eb7\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u6536\u5230\u836f\u54c1\u6ce8\u518c\u53d7\u7406\u901a\u77e5\u4e66\u7684\u516c\u544a-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6cf0\u6069\u5eb7\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u6536\u5230\u836f\u54c1\u6ce8\u518c\u53d7\u7406\u901a\u77e5\u4e66\u7684\u516c\u544a (1).\"><\/object><a id=\"wp-block-file--media-657686dc-940e-493d-8a86-5ae52d1d433a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u6cf0\u6069\u5eb7\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u6536\u5230\u836f\u54c1\u6ce8\u518c\u53d7\u7406\u901a\u77e5\u4e66\u7684\u516c\u544a-1.pdf\">\u6cf0\u6069\u5eb7\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u6536\u5230\u836f\u54c1\u6ce8\u518c\u53d7\u7406\u901a\u77e5\u4e66\u7684\u516c\u544a (1)<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/\u6cf0\u6069\u5eb7\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u6536\u5230\u836f\u54c1\u6ce8\u518c\u53d7\u7406\u901a\u77e5\u4e66\u7684\u516c\u544a-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-657686dc-940e-493d-8a86-5ae52d1d433a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41874,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[31,38,2833,2832],"class_list":["post-41873","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-generic-drugs","tag-market-approval-filings","tag-she-301263","tag-taienkang-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Guangdong Taienkang Secures NMPA Approval for Safinamide Generic - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for safinamide tablets, approving the drug as a Category\u202f4 chemical product. The decision paves the way for Taienkang\u2019s version of the Parkinson\u2019s disease (PD) adjunctive therapy to reach Chinese patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41873\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic\" \/>\n<meta property=\"og:description\" content=\"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for safinamide tablets, approving the drug as a Category\u202f4 chemical product. The decision paves the way for Taienkang\u2019s version of the Parkinson\u2019s disease (PD) adjunctive therapy to reach Chinese patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41873\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-19T07:48:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-19T07:48:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1904.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41873#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41873\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic\",\"datePublished\":\"2025-09-19T07:48:12+00:00\",\"dateModified\":\"2025-09-19T07:48:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41873\"},\"wordCount\":276,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41873#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1904.webp\",\"keywords\":[\"Generic drugs\",\"Market approval filings\",\"SHE: 301263\",\"Taienkang Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41873#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41873\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41873\",\"name\":\"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41873#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41873#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1904.webp\",\"datePublished\":\"2025-09-19T07:48:12+00:00\",\"dateModified\":\"2025-09-19T07:48:13+00:00\",\"description\":\"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for safinamide tablets, approving the drug as a Category\u202f4 chemical product. The decision paves the way for Taienkang\u2019s version of the Parkinson\u2019s disease (PD) adjunctive therapy to reach Chinese patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41873#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41873\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41873#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1904.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1904.webp\",\"width\":1080,\"height\":608,\"caption\":\"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41873#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic - Insight, China&#039;s Pharmaceutical Industry","description":"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for safinamide tablets, approving the drug as a Category\u202f4 chemical product. The decision paves the way for Taienkang\u2019s version of the Parkinson\u2019s disease (PD) adjunctive therapy to reach Chinese patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41873","og_locale":"en_US","og_type":"article","og_title":"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic","og_description":"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for safinamide tablets, approving the drug as a Category\u202f4 chemical product. The decision paves the way for Taienkang\u2019s version of the Parkinson\u2019s disease (PD) adjunctive therapy to reach Chinese patients.","og_url":"https:\/\/flcube.com\/?p=41873","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-19T07:48:12+00:00","article_modified_time":"2025-09-19T07:48:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1904.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41873#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41873"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic","datePublished":"2025-09-19T07:48:12+00:00","dateModified":"2025-09-19T07:48:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41873"},"wordCount":276,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41873#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1904.webp","keywords":["Generic drugs","Market approval filings","SHE: 301263","Taienkang Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41873#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41873","url":"https:\/\/flcube.com\/?p=41873","name":"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41873#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41873#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1904.webp","datePublished":"2025-09-19T07:48:12+00:00","dateModified":"2025-09-19T07:48:13+00:00","description":"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced that the National Medical Products Administration (NMPA) has accepted its marketing application for safinamide tablets, approving the drug as a Category\u202f4 chemical product. The decision paves the way for Taienkang\u2019s version of the Parkinson\u2019s disease (PD) adjunctive therapy to reach Chinese patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41873#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41873"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41873#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1904.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1904.webp","width":1080,"height":608,"caption":"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41873#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Guangdong Taienkang Secures NMPA Approval for Safinamide Generic"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1904.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41873","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41873"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41873\/revisions"}],"predecessor-version":[{"id":41876,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41873\/revisions\/41876"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41874"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41873"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41873"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}